J.P. Morgan has cut its recommendation on Coloplast to "underweight" from "neutral," reflecting what the broker describes as a widening gap between the medtech company's market valuation and its weakening earnings outlook. The downgrade was announced in a note dated Wednesday and coincided with the stock falling just over 3% on the session.
The bank reduced its December 2027 price target to 377 Danish crowns from 484 crowns. That revised target implies roughly an 18% downside from Coloplast's September 8 closing price of 446.70 crowns.
Coloplast has a market capitalization of $15.11 billion, with 218 million shares outstanding. The company's 52-week trading range spans from 637.80 crowns at the high to 369.70 crowns at the low.
Valuation versus earnings trajectory
J.P. Morgan's coverage, now led by analyst Anchal Verma, points out that Coloplast trades at about 18 times projected 2027 earnings. The broker notes that this multiple represents a roughly 20% premium to the broader European medtech sector even though Coloplast's expected earnings growth is about 20% below that sector.
According to the note, such a premium could only be justified if earnings-per-share (EPS) growth reaches the high-single-digit to low-double-digit range. J.P. Morgan's own forecast, by contrast, calls for just 3% EPS growth in fiscal 2027.
Under the new 377-crown target, the stock's implied trading multiple falls to about 14.5 times, which J.P. Morgan says is broadly in line with the European medtech sector.
Scenario-weighted price target and timing
The new price target reflects a probability-weighted approach across three mid-term guidance scenarios. J.P. Morgan expects Coloplast's incoming chief executive to revise fiscal year results on November 3, and structured its outlook to reflect alternative guidance outcomes.
- Bear case (40% probability): Sales growth guidance cut to 5-6% and margin compression to about 25% due to growth investments. This outcome implies approximately 30% downside and a target of 313 crowns.
- Base case (50% probability): Sales growth of 6-7% with margins steady, implying roughly 10% downside and a target of 411 crowns.
- Bull case (10% probability): The current 7-8% growth target is maintained, implying 3% upside and a target of 470 crowns.
Analyst adjustments to forecasts
J.P. Morgan lowered its fiscal 2027 adjusted EPS estimate to 27.20 crowns from 27.58 crowns, a reduction of 1.4%. It also trimmed its fiscal 2027 group sales estimate to 30.83 billion crowns from 30,958 million crowns previously, a decrease of 0.4%.
The broker noted that the stock has already declined about 25% over the past twelve months, but argued that Coloplast's earnings profile has continued to deteriorate and that additional downgrades are likely. On that basis, J.P. Morgan said the shares should trade in line with or at a discount to the sector, rather than maintaining their premium valuation.
Near-term execution concerns cited by J.P. Morgan
The note listed three specific near-term issues that underpin the cautious stance.
- Challenges improving commercial execution in the U.S. chronic care channel, where Coloplast faces competition from Convatec.
- Continued softness in the biologics market at Kerecis following reimbursement changes.
- Ongoing cost inflation, with the broker pointing out that reported EBIT margins have declined by more than four percentage points over the last five years.
Key risks to the underweight rating and potential upside triggers
J.P. Morgan identified the primary risk to its underweight rating as a mid-term guidance reset that clears the way for Coloplast's new CEO to execute effectively, which could support a re-rating. The broker outlined several upside scenarios that would challenge its cautious view:
- A return to high-single-digit organic sales growth;
- Margins recovering to around 30%; and
- Improved capital allocation, including reducing leverage below two times and maintaining the dividend policy.
For now, J.P. Morgan's downgrade and revised targets are anchored in the view that Coloplast's earnings momentum is lagging peers, leaving a valuation premium difficult to defend absent a clear improvement in growth and margins.